Singapore, July 21 -- Fangzhou Inc. has announced the launch of Kyinsu(R), the world's first once-weekly basal insulin/GLP-1 RA combination therapy, on its Internet hospital platform, further expanding its collaboration with global healthcare company Novo Nordisk to improve access to innovative diabetes treatments through AI-powered chronic disease management services.

China is the first market globally to commercialise Kyinsu(R), making Fangzhou one of the product's key launch partners. Leveraging its AI-enabled chronic disease management ecosystem and nationwide pharmaceutical supply chain, the company aims to accelerate patient access to the new therapy while supporting long-term treatment management.

Built around its AI+H2H (Hospita...